33996-33-7
中文名称
N-乙酰-L-4-羟基脯氨酸
英文名称
Oxaceprol
CAS
33996-33-7
EINECS 编号
251-780-6
分子式
C7H11NO4
MDL 编号
MFCD00037339
分子量
173.17
MOL 文件
33996-33-7.mol
更新日期
2025/05/09 16:22:26
33996-33-7 结构式
基本信息
中文别名
N-乙酰-L-4-羟基脯氨酸N-乙酰-L-羟脯氨酸
奥沙西罗
酰羟氢吡咯酸
1-乙酰基-4-羟基吡咯烷羧酸
4-羟基-N-乙酰基脯氨酸
反式-1-乙酰基-4-羟基-L-脯氨酸
N-乙酰-4-羟基-L-脯氨酸
N-乙酰-4-羟基脯氨酸
N-乙酰-L-羟基脯氨酸
英文别名
(2S,4R)-4-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID(4R,2S)-1-ACETYL-4-HYDROXY-PYRROLIDINE-2-CARBOXYLIC ACID
ACETYL-4-HYDROXY-L-PROLINE
ACETYL-L-4-HYDROXYPROLINE
AC-HYDROXYPROLINE
AC-HYP-OH
N-ACETYL-4-HYDROXY-L-PROLINE
N-ACETYLHYDROXY-L-PROLINE
N-ACETYL-L-HYDROXYPROLINE
N-AC-L-HYP
N-ALPHA-ACETYL-L-4-TRANS-HYDROXYPROLINE
N-ALPHA-ACETYL-L-HYROXYPROLINE
N-ALPHA-ACETYL-TRANS-4-HYROXY-L-PYROLLIDINE
OXACEPROL
TRANS-1-ACETYL-4-HYDROXY-L-PROLINE
trans-l-prolin
(R)-N-Acetyl-4-hydroxy-L-proline
N-Acetyl-4-hydroxyproline
N-Acetylhydroxyproline
N-Acetyl-trans-4-hydroxy-L-proline
所属类别
生物化工：脯氨酸类衍生物物理化学性质
熔点132-133 °C (dec.)(lit.)
比旋光度-119 º (c=4 in H2O)
沸点303.8°C (rough estimate)
密度1.3346 (rough estimate)
蒸气压0Pa at 20℃
折射率1.4490 (estimate)
储存条件Store at RT.
溶解度DMSO : ≥ 32 mg/mL (184.79 mM)
酸度系数(pKa)3.48±0.40(Predicted)
形态结晶粉末
颜色白色
旋光性 (optical activity)[α]20/D 119°, c = 4 in H2O
Merck14,6903
BRN84043
InChIKeyBAPRUDZDYCKSOQ-RITPCOANSA-N
LogP-1.51 at 20℃
N-乙酰-L-4-羟基脯氨酸价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/02/08 | HY-17490 | N-乙酰-L-4-羟基脯氨酸 Oxaceprol | 33996-33-7 | 1g | 100元 |
| 2025/02/08 | HY-17490 | N-乙酰-L-4-羟基脯氨酸 Oxaceprol | 33996-33-7 | 10mM * 1mLin DMSO | 110元 |
| 2025/02/08 | HY-17490 | N-乙酰-L-4-羟基脯氨酸 Oxaceprol | 33996-33-7 | 5 g | 250元 |
常见问题列表
生物活性
Oxaceprol (N-acetyl-L-hydroxyproline) 是一种抗炎性药物，用于治疗骨关节炎。体内研究
Oxaceprol, at 6 mg/kg/day for 7 days, significantly reduces both the surface area and wet weight of cotton pellet granulomas, being slightly less effective than indomethacin, 3 mg/kg.
Oxaceprol (6–54 mg/kg/day) given therapeutically had no effect on the primary paw oedema response, but inhibits secondary lesions in the ears and tail.
Oxaceprol does not inhibit the synthesis of prostaglandins in vitro, but markedly inhibits neutrophil infiltration into the joints of rats with adjuvant arthritis.
| Animal Model: | Male Sprague-Dawley rats. |
| Dosage: | 18, 50 or 150 mg/kg. |
| Administration: | Gavage daily for 15 days. |
| Result: | Produced comparable inhibition of hyperalgesia to that produced by indomethacin. |